ProMIS Q2 net loss $11.7M; PRECISE-AD interim shows no ARIA-E, biomarker declines

ProMIS Neurosciences Inc.

2026-Q2 EPS reported -$2.54

Q2 2026 net loss $11.7M ($1.28/share) vs $10.1M ($7.26/share) in Q2 2025.
Cash and short-term investments $53.4M at June 30, 2026, up from $6.1M at Dec 31, 2025; $70.1M net proceeds from Jan 2026 private placement.
PRECISE-AD interim (136 patients): zero ARIA-E cases; 4.4% total ARIA (all mild ARIA-H); plasma pTau217 -15%, CSF MTBR-tau243 -13.3% in blinded pooled analysis.
Expects unblinded 12-month topline data (cognitive outcomes) in Q1 2027; cash runway through 2027.
Pipeline: PMN267 (TDP-43) and PMN442 (alpha-synuclein) advancing toward IND-enabling studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.